Kerendia 20mg Tablet 14s (Finerenone) is a pioneering pharmacological agent classified as a non-steroidal mineralocorticoid receptor antagonist (MRA). It is specifically engineered to address the complex pathological challenges of Chronic Kidney Disease (CKD) in adult patients who are also living with Type 2 Diabetes (T2D). Unlike older generations of mineralocorticoid antagonists, which were steroidal, Finerenone offers a more selective and potent binding profile. Its primary clinical objective is to mitigate the progression of kidney damage and reduce the associated risks of cardiovascular complications, such as heart failure and myocardial infarction. By targeting the mineralocorticoid receptor, a key driver of inflammation and tissue scarring, this medication helps to preserve the structural integrity of the kidneys and the heart.
Delivery by
...
WHO GMP Certified
Long Expiry (>8 Months)
15 Days Easy Returns
Genuine Medicine
Pay On Delivery
Secure Payment
LegitScript Certified Online Pharmacy
View content in
Kerendia 20mg Tablet 14s (Finerenone) is a pioneering pharmacological agent classified as a non-steroidal mineralocorticoid receptor antagonist (MRA). It is specifically engineered to address the complex pathological challenges of Chronic Kidney Disease (CKD) in adult patients who are also living with Type 2 Diabetes (T2D). Unlike older generations of mineralocorticoid antagonists, which were steroidal, Finerenone offers a more selective and potent binding profile. Its primary clinical objective is to mitigate the progression of kidney damage and reduce the associated risks of cardiovascular complications, such as heart failure and myocardial infarction. By targeting the mineralocorticoid receptor, a key driver of inflammation and tissue scarring, this medication helps to preserve the structural integrity of the kidneys and the heart.
Kerendia 20mg Tablet 14s represents a significant milestone in the evolution of nephrology and cardiology. For decades, the management of diabetic kidney disease was primarily limited to blood pressure and blood sugar control. However, the discovery of the mineralocorticoid receptor (MR) as a major contributor to organ damage opened the door for Finerenone.
The Role of the Mineralocorticoid Receptor
The mineralocorticoid receptor is a protein found in various tissues, including the kidneys, heart, and blood vessels. Normally, it responds to the hormone aldosterone to help regulate the body's salt and water balance. However, in patients with chronic conditions like diabetes, these receptors often become overactivated. This overactivation does not just affect fluid balance; it triggers a cascade of negative biological responses. It stimulates the production of pro-inflammatory cytokines and promotes fibrosis (the formation of excessive connective tissue or scarring). Over time, this scarring replaces healthy kidney filters (nephrons) and stiffens the heart muscle, leading to a steady decline in organ function.
Steroidal vs. Non-Steroidal MRAs
The "non-steroidal" nature of Finerenone is what distinguishes it from earlier medications like spironolactone or eplerenone. Older steroidal MRAs often cross-react with other hormone receptors, such as those for testosterone and progesterone, leading to unwanted side effects like breast tenderness or enlargement in men (gynecomastia). Finerenone is highly selective, meaning it binds almost exclusively to the mineralocorticoid receptor, significantly reducing the risk of hormonal disturbances. Furthermore, Finerenone distributes more evenly between the heart and kidneys, whereas older MRAs tend to accumulate more heavily in the kidneys. This balanced distribution allows Finerenone to provide robust cardiovascular protection alongside its renal benefits, making it a "dual-action" protector for diabetic patients.
Impact on Clinical Outcomes
In large-scale clinical observations, patients taking Finerenone 10mg demonstrated a slowed decline in the Estimated Glomerular Filtration Rate (eGFR), which is the standard measure of how well the kidneys are filtering waste. Additionally, the medication has shown a remarkable ability to reduce albuminuria (the presence of protein in the urine), which is an early and critical sign of kidney stress. By calming the inflammatory storm within the renal and cardiac tissues, Finerenone helps patients stay away from end-stage renal disease and the need for dialysis or transplantation.
Kerendia 20mg Tablet 14s (Finerenone 10mg) is utilised for a specific range of chronic therapeutic goals:
To slow the progression of kidney failure in adults with CKD associated with Type 2 Diabetes.
To reduce the risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death.
Specifically used to lower the risk of hospitalisation for heart failure in the diabetic patient population.
Indicated to reduce the risk of non-fatal heart attacks in high-risk patients with renal impairment.
It directly inhibits the pathways that lead to kidney scarring, offering a level of protection that blood sugar control alone cannot provide.
Relaxing the MR activity in cardiac tissues helps prevent the stiffening of the heart chambers, reducing the likelihood of heart failure.
Due to its non-steroidal structure, it avoids the feminising side effects in men and menstrual irregularities in women associated with older MRAs.
While it can raise potassium levels, Finerenone has shown a lower incidence of severe hyperkalemia compared to older steroidal antagonists when monitored correctly.
It works effectively alongside standard treatments like ACE inhibitors, ARBs, and SGLT2 inhibitors, providing an additional layer of defence for the organs.
While Finerenone is generally well-tolerated, its influence on electrolyte balance and blood pressure necessitates careful observation.
Finerenone functions through a highly specific molecular blockade of the Mineralocorticoid Receptor (MR).
The standard starting dose for most patients is 10mg or 20mg once daily, depending on the patient's current eGFR and potassium levels. For many, the 10mg dose is used initially and may be increased to 20mg after 4 weeks if blood tests remain within a safe range.
An overdose of Finerenone 10mg is most likely to result in Hyperkalemia.
Therapeutic Class
Nephroprotective / Cardiovascular
Action Class
Non-steroidal Mineralocorticoid Receptor Antagonist
Chemical Class
Dihydropyridine derivative
Habit Forming
No
PlatinumRx is committed to providing reliable and accurate information to support informed customer decisions. However, all information made available on the Platform, including product descriptions, comparisons, and other content, is provided solely for general informational purposes. Such information is not intended to diagnose, prevent, treat, or cure any medical condition, nor should it be relied upon as a substitute for professional medical advice, diagnosis, or treatment.

More Medicines By Manufacturer
More Medicines With Salt
Top Selling Medicines
Top Selling Devices